Platelet RNA Reveals Hidden Molecular Fingerprints of Glioblastoma in a Simple Blood Test

Glioblastoma is the deadliest cancer that begins in the brain, and it announces itself with a median survival of only about fifteen months after diagnosis. Its cells infiltrate healthy tissue so diffusely that surgery, radiation, and chemotherapy can rarely remove every trace, and its low tumor mutational burden means that no single genetic mutation reliably betrays its presence. Now, a re-analysis of one of the largest platelet RNA sequencing datasets ever assembled for this disease suggests that the answer may not lie in the tumor at all, but in tiny cell fragments circulating in the blood. By combining two complementary computational strategies, researchers have shown that the RNA carried by platelets from glioblastoma patients carries distinct molecular fingerprints of the disease, opening a window onto systemic biology that a brain biopsy could never easily provide.

Platelets have long been dismissed as simple clotting agents, fragments of megakaryocytes whose job is to plug wounds. Over the past decade, however, they have been recast as sophisticated sentinels of disease. Tumors educate platelets: they release vascular endothelial growth factor and other pro-angiogenic signals, shield circulating tumor cells from immune attack, and swap molecular information with the tumor microenvironment. Because platelets internalize and process RNA from the conditions they encounter, their transcriptome acts as a circulating diary of systemic illness. The new study, published in Cancer Reports, revisits publicly available platelet RNA-sequencing data from 84 treatment-naive glioblastoma patients and 319 healthy controls, refining the original cohort by excluding astrocytoma grade IV cases to match the WHO 2021 definition of glioblastoma as an IDH-wildtype grade 4 diffuse astrocytic tumor, and removing a small batch of control samples affected by a technical artifact.

The analytical design is what makes the study interesting to computational biologists. Rather than relying on a single method, the team ran two deliberately different approaches on the same dataset of 4,412 expressed genes. The first, Gene Set Enrichment Analysis, or GSEA, ignores arbitrary significance cutoffs and instead ranks the entire transcriptome, asking whether known biological pathways shift in a coordinated way between patients and controls. The second, threshold-based differential expression analysis followed by Elastic Net regularization, is a machine learning workflow: DESeq2 first narrows thousands of genes to 323 candidates with fold changes above 1.3 and a false discovery rate below 0.1, and then a penalized logistic regression model shrinks most coefficients to zero, retaining only the most informative predictors. The result was a compact 103-gene signature that distinguishes glioblastoma from healthy blood with striking accuracy.

That accuracy is the headline number. Evaluated on an independent test set kept completely separate during model development, the 103-gene platelet signature achieved an area under the curve of 0.99 with a misclassification rate of just five percent. Across ten random repetitions of the entire procedure, the mean AUC held at 0.989, with mean sensitivity of 0.877 and specificity of 0.980. Crucially, the team did not stop there. They compared their signature against 100 randomly generated 103-gene panels, and while random genes also performed surprisingly well in this high-dimensional setting, the real signature consistently outperformed the random reference distribution in both AUC and balanced accuracy. In an additional external platelet RNA cohort, without any genome-wide feature selection, the signature still achieved an AUC of 0.93, evidence that the signal is at least partly transferable across laboratories and sequencing pipelines.

The GSEA arm of the study tells a different, more mechanistic story. Positively enriched pathways in patients clustered around core platelet biology: blood coagulation, platelet activation, wound healing, vascular and circulatory processes, cytoskeletal organization, and extracellular matrix remodeling. To tame the redundancy inherent in Gene Ontology terms, the researchers applied a Markov clustering framework, grouping the enriched terms into 22 clusters that spanned vascular processes, RNA processing, ribosomal function, immune regulation, autophagy, and cellular metabolism. Because GSEA results can depend on the random seed, the entire enrichment analysis was repeated ten times with different seeds, and the top pathways proved highly consistent across iterations. Notably, transcripts associated with ribosomal function and protein synthesis were downregulated in patient platelets, echoing earlier reports of suppressed translation-related programs in tumor-educated platelets.

Perhaps the most puzzling finding was the enrichment of bacterial response pathways in the predictive gene signature, given that none of the patients showed signs of infection when their blood was drawn. The authors propose a plausible explanation rooted in damage-associated molecular patterns, or DAMPs. Necrotic cells deep inside glioblastoma release these molecules, which activate Toll-like receptors on platelets and effectively mimic the molecular alarm signals that bacteria trigger. In other words, a tumor that never hosted an infection can still make the platelet transcriptome look as if one were raging. This sterile-inflammation mechanism could help explain the chronic inflammatory tone that glioblastoma cultivates systemically, and it fits with the description of tumors as wounds that refuse to heal, perpetually regenerating tissue that recruits myeloid cells, fuels angiogenesis, and remodels the extracellular matrix.

The predictive genes themselves sketch a portrait of immune and cellular dysfunction. Elevated transcripts included B2M and LGALS2, both implicated in immune evasion, while downregulated genes such as CXCR2P1 and OAS1 hint at blunted anti-tumor interferon responses. Genes tied to proliferation, including CAMK2D and PIK3IP1, to metabolism, including MAOB and FKBP5, and to epigenetic regulation, such as the chromatin factor CBX7, round out the panel. The authors are careful to stress a critical caveat: Elastic Net selects genes for predictive power, not proven mechanism, and the Gene Ontology analysis of the 103-gene panel yielded no terms surviving multiple-testing correction, so the functional annotations attached to the signature are explicitly descriptive rather than definitive evidence of pathway overrepresentation.

To test whether the strongest platelet signals reflect anything real about the tumor microenvironment, the team turned to independent glioma datasets. In bulk RNA data spanning multiple glioma grades, platelet activation and aggregation signatures correlated strongly with wound healing signatures, and wound healing programs were elevated in glioma patients compared with normal controls. Single-cell RNA sequencing data analyzed with a pseudobulk approach confirmed the pattern on two different platforms, 10x Genomics and SMART-Seq, with the correlation between platelet activation and wound healing scores appearing even stronger in the SMART-Seq samples. Because high-quality external platelet RNA cohorts remain scarce, this cross-dataset triangulation is supportive rather than a direct replication, but it suggests that the platelet transcriptome is genuinely tracking tumor-associated biology rather than laboratory noise.

The study is candid about its limits. The cohort, though large by platelet RNA standards, still contains a modest number of glioblastoma cases; the thresholds used for gene selection are conventional rather than biologically derived; and clinical annotation was too incomplete to rule out confounding by medications or other conditions that also reprogram platelets. Many platelet activation signatures are shared across cancers and inflammatory diseases, so the findings cannot be treated as glioblastoma-specific without further validation, and pathway annotations curated from nucleated cells must be interpreted cautiously when applied to anucleate platelets. Even so, the work demonstrates that a routine blood draw, read through the right computational lens, can reveal coordinated systemic responses to one of medicine’s most formidable tumors, and it lays a concrete foundation for larger, fully annotated studies that could one day turn tumor-educated platelets into a non-invasive diagnostic and monitoring tool for brain cancer.

Subject of Research: Platelet-derived RNA biomarkers for glioblastoma detection

Article Title: Deepening the Understanding of Platelet‐Derived RNA as Biomarker for Glioblastoma Through GSEA, TDEA, and Elastic Net Regularization Analysis

Article References: Giczewska, A., Pastuszak, K., van Hout, L., Post, E., Ramaker, J., Zwaan, K., Supernat, A., & Westerman, B. A. (2026). Deepening the Understanding of Platelet‐Derived RNA as Biomarker for Glioblastoma Through GSEA , TDEA , and Elastic Net Regularization Analysis. Cancer Reports, 9(10), Article e70656. https://doi.org/10.1002/cnr2.70656

Image Credits: AI Generated

DOI: 10.1002/cnr2.70656

Keywords: glioblastoma, platelet RNA, tumor-educated platelets, liquid biopsy, GSEA, Elastic Net, biomarker, RNA sequencing, tumor microenvironment, DAMPs, machine learning, blood-based diagnostics